Welcome to industryreportstore.com

Need help? +44(0)20 7936 6830

Alzheimer's Disease market research, reports and industry analysis

mail

Contact us for professional industry advice

Email us or call

+44(0)20 7936 6830
mail

for FREE research alerts
to your inbox

17 Item(s)

Page 1 of 2

  1. Global Human Albumin Market 2016-2020

    By: Technavio
    , Published: Jun-2016
    , Product code: IRTNTR9576
    The report covers the present scenario and the growth prospects of the global human albumin market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded and generic albumin drugs used to treat infections, liver diseases, shock, during surgery, and severe burns. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched in the market along with the decline in revenues from the genericization of the marketed drugs during the forecast period.
    $2,500.00

  2. Global Alzheimer's Disease Partnering 2010 to 2016

    By: Current Partnering
    , Published: Apr-2016
    , Product code: CP2204alz
    Provides understanding and access to the Alzheimer's disease partnering deals and agreements entered into by the worlds leading healthcare companies.
    $1,495.00

  3. Alzheimer’s Therapeutics in Asia-Pacific Markets to 2021 - Growth Driven by Rising Prevalence, Growing Awareness and Expected Launch of Disease Modifying Therapies

    By: GBI Research
    , Published: Mar-2016
    , Product code: GBIHC404MR
    Alzheimer’s Disease (AD) is an irreversible, progressive neurodegenerative disease, characterized by cognitive impairment, memory loss and functional decline. Symptoms typically begin to first occur in patients in their mid-sixties, appearing in varying stages. The pathological features of AD comprise histopathological changes within the brain. Mild Cognitive Impairment (MCI) is a heterogeneous condition between normal cognition and dementia, whereby cognitive changes in mental abilities, such as memory or thinking, are affected. Almost all cases of AD begin with MCI, but it should be noted that not all patients with MCI go on to develop AD.
    $4,995.00

  4. Alzheimer’s Disease Therapeutics in Major Developed Markets to 2021 - Aging Population and Improved Disease Understanding Increase Demand for Disease Modifying Agents

    By: GBI Research
    , Published: Feb-2016
    , Product code: GBIHC399MR
    Alzheimer's Disease (AD) is an irreversible, progressive neurodegenerative disease, characterized by cognitive impairment, memory loss and functional decline. Symptoms typically begin to first appear in patients in their mid-sixties, with symptoms appearing in varying stages. The pathological features of AD comprise histopathological changes within the brain. Mild Cognitive Impairment (MCI) is a heterogeneous condition between normal cognition and dementia, whereby cognitive changes in mental abilities, such as memory or thinking, are affected. Almost all cases of AD begin with MCI, but it should be noted that not all patients with MCI go on to develop AD.
    $4,995.00

  5. Alzheimer's Disease - Pipeline Review, H1 2015

    By: Global Markets Direct
    , Published: Jan-2015
    , Product code: GMDHC6229IDB
    Global Markets Direct’s, ‘Alzheimer's Disease - Pipeline Review, H1 2015’, provides an overview of the Alzheimer's Disease’s therapeutic pipeline.
    $2,500.00

  6. Trends in Therapeutic Partnering

    By: Current Partnering
    , Published: Aug-2014
    , Product code: CP2290-
    Provides a detailed understanding and analysis of the 35 most popular therapeutic targets for partnering in the period 2009 to mid 2014
    $3,995.00

  7. Global Alzheimer's Drugs Market 2014-2018

    By: Technavio
    , Published: Jun-2014
    , Product code: IRTNTR3675
    About Alzheimer’s Disease Alzheimer's disease is a progressive, irreversible degeneration of the brain that disrupts the thinking, language, behavioral and cognitive skills of a person. AD is more prevalent in people aged 65 years or above and affects women more than men. Globally, 35 million people are suffering from AD and this number is expected to double by 2030. AD arises due to the failure of synaptic transmission, which results in eventual death of the neurons present in the brain. AD is characterized by the accumulation of beta-amyloid plaques outside and around the neurons and the formation of neurofibrillary tangles inside the nerve cells. Neuronal loss associated with AD leads to a reduction in brain size and deposition of debris from dead and dying neurons inside the brain. AD can be categorized into Early-onset AD, Late-onset AD, and Familial AD. Early-onset AD is a rare form of AD that affects people younger than 65 years of age. Late-onset AD is the most prevalent form of AD and usually affects people aged 65 years or above. Familial AD is the inheritable form of AD with least prevalence among the three.
    $3,000.00

  8. PharmaPoint: Alzheimer’s Disease - China Drug Forecast and Market Analysis to 2022

    By: GlobalData
    , Published: Jul-2013
    , Product code: GDHC158CFR-
    GlobalData has released its new Country report, “PharmaPoint: Alzheimer’s Disease - China Drug Forecast and Market Analysis to 2022”. There are no long-term effective therapies for Alzheimer’s Disease (AD), so this remains at the top of the list for unmet needs. While physicians agree that symptomatic therapies are relatively safe and effective, these therapies are still lacking because of they cannot maintain their effects and lack mechanisms that alter the course of the disease.
    $4,995.00

  9. PharmaPoint: Alzheimer’s Disease - Current and Future Players

    By: GlobalData
    , Published: Jul-2013
    , Product code: GDHC1020FPR-
    GlobalData has released its pharma report, “PharmaPoint: Alzheimer’s Disease - Current and Future Players”. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Alzheimer’s Disease Market. The report identifies and analyses the key companies shaping and driving the global Alzheimer’s Disease market. The report provides insight into the competitive Alzheimer’s Disease landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData’s team of industry experts.
    $2,995.00

  10. PharmaPoint: Alzheimer’s Disease - France Drug Forecast and Market Analysis to 2022

    By: GlobalData
    , Published: Jul-2013
    , Product code: GDHC152CFR-
    GlobalData has released its new Country report, “PharmaPoint: Alzheimer’s Disease - France Drug Forecast and Market Analysis to 2022”. There are no long-term effective therapies for Alzheimer’s Disease (AD), so this remains at the top of the list for unmet needs. While physicians agree that symptomatic therapies are relatively safe and effective, these therapies are still lacking because of they cannot maintain their effects and lack mechanisms that alter the course of the disease.
    $4,995.00

17 Item(s)

Page 1 of 2